Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of a novel somatostatin analog (SSA) for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushings disease, and diabetic retinopathy.
Aspireos sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and an innovative backbone cyclization technology used for stabilization of the peptide.
During extensive preclinical testing, Somatoprim has demonstrated a receptor binding and pharmacological profile thatis significantly differentiated from SSAs that are currently marketed or in clinical development. In particular, Somatoprim has demonstrated an improved side effect profile with minimal adverse effects on the gastrointestinal tract and metabolic control.
Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim suggests that it has the potential to significantly increase the response rate of acromegalic patients to SSA therapy.
Aspireos only investor is TVM Capital, a dedicated provider of equity capital to the international pharmaceutical, biopharmaceutical, medical technology, and healthcare diagnostics industries. Aspireo is an Israeli company that was established by TVM Capital as a Project Focused Company (PFC). Aspireo and the Somatoprim project are managed by a team of dedicated and experienced executives that are supported by a group of collaborators and consultants with complementary knowledge and skills.